Literature DB >> 6221382

Pharmacokinetics of cefoperazone in patients with normal and impaired hepatic and renal function.

R A Greenfield, A U Gerber, W A Craig.   

Abstract

The pharmacokinetics of cefoperazone in normal subjects and in patients with hepatic and renal dysfunction are reviewed. Peak serum concentrations and areas under serum level-time curves are linearly related to dose. The range of mean peak serum concentrations after a 2-g dose of cefoperazone is 202-375 micrograms/ml with iv injection or infusion and 111 micrograms/ml with im injection. The serum half-life is 1.6-2.6 hr. Urinary excretion is rapid, but only 15%-37% of the dose is recovered in urine. The drug is not metabolized significantly. Levels of drug in bile are many times higher than serum levels, and biliary excretion represents the major pathway of cefoperazone elimination. Serum kinetics of cefoperazone are not significantly altered by renal impairment. However, hepatic dysfunction is associated with a two- to fourfold increase in serum half-life. Even in these patients, drug accumulation was not observed after repeated administration of 1 g of cefoperazone at 12-hr intervals. Major dosage modification should only be required with concomitant renal and hepatic dysfunction.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6221382     DOI: 10.1093/clinids/5-supplement_1.s127

Source DB:  PubMed          Journal:  Rev Infect Dis        ISSN: 0162-0886


  15 in total

1.  Reversible encephalopathy induced by cefoperazone: a case report monitored with EEG.

Authors:  Stefano Pro; F Randi; P Pulitano; E Vicenzini; O Mecarelli
Journal:  Neurol Sci       Date:  2010-10-07       Impact factor: 3.307

Review 2.  BDDCS Predictions, Self-Correcting Aspects of BDDCS Assignments, BDDCS Assignment Corrections, and Classification for more than 175 Additional Drugs.

Authors:  Chelsea M Hosey; Rosa Chan; Leslie Z Benet
Journal:  AAPS J       Date:  2015-11-20       Impact factor: 4.009

3.  Penetration of cefoperazone into ascites.

Authors:  A Van Gossum; M Quenon; M Van Gossum; A Herchuelz; J P Thys
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

4.  Multiple-dose pharmacokinetics and toleration of intravenously administered cefoperazone and sulbactam when given as single agents or in combination.

Authors:  D P Reitberg; T J Whall; M Chung; D Blickens; H Swarz; J Arnold
Journal:  Antimicrob Agents Chemother       Date:  1988-01       Impact factor: 5.191

5.  Alteration of hemostasis associated with cefoperazone treatment.

Authors:  K Andrassy; J Koderisch; S Fritz; H Bechtold; H Sonntag
Journal:  Infection       Date:  1986 Jan-Feb       Impact factor: 3.553

6.  Pharmacokinetics of cefoperazone in the parturient.

Authors:  B Gonik; S Feldman; L K Pickering; C G Doughtie
Journal:  Antimicrob Agents Chemother       Date:  1986-12       Impact factor: 5.191

7.  Pharmacokinetic properties of the newer cephalosporins. A valid basis for drug selection?

Authors:  J T Noble; M Barza
Journal:  Drugs       Date:  1985-09       Impact factor: 9.546

8.  The pharmacokinetics of new cephalosporins: significance in clinical practice.

Authors:  H C Neu
Journal:  Bull N Y Acad Med       Date:  1984-05

Review 9.  Considerations in dosage selection for third generation cephalosporins.

Authors:  J H Yuk-Choi; C H Nightingale; T W Williams
Journal:  Clin Pharmacokinet       Date:  1992-02       Impact factor: 6.447

10.  Pharmacokinetics of cefoperazone (2.0 g) and sulbactam (1.0 g) coadministered to subjects with normal renal function, patients with decreased renal function, and patients with end-stage renal disease on hemodialysis.

Authors:  D P Reitberg; D A Marble; R W Schultz; T J Whall; J J Schentag
Journal:  Antimicrob Agents Chemother       Date:  1988-04       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.